Huitai Medical announced that the company voluntarily disclosed production and operation conditions and achieved operating income of 1,526 billion yuan in the first half of 2026, an increase of 25.75%; net profit attributable to shareholders of listed companies was 537 million yuan, an increase of 26.38%; and total profit of 603 million yuan, an increase of 25.84% year on year. The revenue and net profit growth rate for the first three quarters of 2026 increased compared to the first half of the year. For details, please refer to the 2026 third quarter report to be disclosed on October 29. Since its listing, the company has implemented four rounds of repurchases, with a repurchase amount of over 600 million yuan; cumulative cash dividends of 653 million yuan from 2020 to 2025.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.